Major Changes in Chemotherapy Regimens Administered to Breast Cancer Patients During 2000-2008 in the Netherlands-Reference-Cited by-同舟云学术

Major Changes in Chemotherapy Regimens Administered to Breast Cancer Patients During 2000-2008 in the Netherlands

Published:2013-05-12 Issue:4 Volume:19 Page:394-401
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

van Herk-Sukel Myrthe P.P.¹,van de Poll-Franse Lonneke V.,Creemers Geert-Jan²,Lemmens Valery E.P.P.,van der Linden Paul D.³,Herings Ron M.C.,Coebergh Jan Willem W.,Voogd Adri C.

Affiliation:

1. PHARMO Institute for Drug Outcomes Research; Utrecht; The Netherlands

2. Department of Oncology; Catharina Hospital; Eindhoven; The Netherlands

3. Hospital pharmacy; Tergooi Hospital; Blaricum; The Netherlands

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.12125/fullpdf

Reference28 articles.

1. Advances in the treatment of breast cancer;Moulder;Clin Pharmacol Ther,2008

2. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer;Lopez-Tarruella;Breast Cancer Res,2009

3. Preoperative chemotherapy treatment of breast cancer-a review;Buzdar;Cancer,2007

4. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer;Tkaczuk;Clin Ther,2009

5. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up;Bonadonna;N Engl J Med,1995

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies;Critical Reviews in Oncology/Hematology;2018-10

2. A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients;Oncotarget;2017-03-22

3. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer;Breast Cancer Research and Treatment;2016-04-23

4. Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice;SpringerPlus;2016-03-31

5. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium;Annals of Oncology;2016-02